Press Releases

You Narrowed By: 2011

Showing 36-70 of 115

First Prev 1 2 3 4 Next Last

2011
September
September 20	Abbott Named Top Dealmaker for Fourth Consecutive Year by The Deal
September 20	Abbott Earns 100 Percent Banned Substance Free Certification for all of its EAS® Sports Nutrition Products
September 15	Abbott Named to Working Mother Magazine’s ‘Best Companies’ List for the Eleventh Consecutive Year
September 15	Abbott Again Recognized as One of the "Top Employers" in the Biotech and Pharmaceutical Industry by Science Magazine
September 15	Abbott Declares 351st Consecutive Quarterly Dividend
September 8	Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
September 8	Abbott Named to the Dow Jones Sustainability Indexes for Seventh Consecutive Year in Recognition of Leading Corporate Citizenship Performance

August
August 31	Abbott to Present at Morgan Stanley Global Healthcare Conference
August 30	Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer
August 30	Abbott Awards CFCareForward Scholarships to 40 Exceptional Graduate and Undergraduate Students Living with Cystic Fibrosis
August 26	Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
August 22	Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
August 22	FDA Clears Abbott’s Genetic FISH Panel for Leukemia Patient Prognosis
August 16	First Patient in Japan Treated with Abbott's Bioresorbable Vascular Scaffold as Part of Global Clinical Trial
August 16	Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market
August 16	Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED® (leuprolide acetate for depot suspension) for the Treatment of Central Precocious Puberty (CPP)
August 11	Abbott’s PediaSure® Brand Aims to Help Moms With Picky Eaters "Take Back the Table" By Building Lifelong Healthy Eating Habits
August 10	Abbott Introduces Vector-borne Pathogen Test to Detect Microorganisms Carried by Ticks and Other Insects
August 10	Abbott Receives U.S. FDA Approval for RX Herculink Elite^® Renal Stent System for Treatment of Renal Artery Disease
August 9	Biogen Idec And Abbott Announce Positive Top-Line Results From The First Registrational Trial For Daclizumab HYP In Relapsing-Remitting Multiple Sclerosis

July
July 28	Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels
July 27	Abbott’s HIV Combo Test Detects Infections Earlier, Provides Valuable Information to Help Prevent Further HIV Transmission and May Save Treatment Costs
July 21	Abbott to Feature Acute HIV Diagnostic, Metabolic Function Tests and Lab Informatics at American Association for Clinical Chemistry Annual Meeting
July 20	Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range

June
June 29	Abbott Hosts Conference Call for Second-Quarter Earnings
June 24	New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients with Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
June 21	Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
June 20	Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot® (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer
June 16	Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes
June 14	Abbott Receives FDA Approval For CREON® (Pancrelipase) Infant-Specific Dosage For Patients With Exocrine Pancreatic Insufficiency Due To Cystic Fibrosis
June 13	New National Survey Results Reveal Majority of Men Find it Easier to Care for Their Car Than for Their Personal Health
June 10	Abbott Declares 350th Consecutive Quarterly Dividend
June 9	Abbott Reports Interim Results from Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease

May
May 26	Abbott Statement on Interim Study Results of AIM-HIGH
May 25	Abbott Receives CE Mark for its RealTime Molecular Test for Cytomegalovirus

First Prev 1 2 3 4 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.